| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Kinase Fusion Gene:PIM3_TRABD |
Kinase Fusion Protein Summary |
 Kinase Fusion gene summary |
| Kinase Fusion partner gene information | Kinase Fusion gene name: PIM3_TRABD | KinaseFusionDB ID: KFG4669 | FusionGDB2.0 ID: KFG4669 | Hgene | Tgene | Gene symbol | PIM3 | TRABD | Gene ID | 415116 | 80305 | |
| Gene name | Pim-3 proto-oncogene, serine/threonine kinase | TraB domain containing | ||||||||||
| Synonyms | pim-3 | LP6054|PP2447 | ||||||||||
| Cytomap | 22q13.33 | 22q13.33 | ||||||||||
| Type of gene | protein-coding | protein-coding | ||||||||||
| Description | serine/threonine-protein kinase pim-3pim-3 oncogeneserine/threonine kinase Pim-3 | traB domain-containing protein | ||||||||||
| Modification date | 20240305 | 20240407 | ||||||||||
| UniProtAcc | Q86V86 | A6NFA1 | ||||||||||
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000360612, | ENST00000303434, ENST00000380909, ENST00000395827, ENST00000395829, | |||||||||
| Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: PIM3 [Title/Abstract] AND TRABD [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | PIM3(50355459)-TRABD(50635670), # samples:1 | |||||||||||
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | PIM3 | GO:0006468 | protein phosphorylation | 18593906 |
| Kinase Fusion gene breakpoints across PIM3 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Kinase Fusion gene breakpoints across TRABD (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
| Kinase Fusion gene information. |
| Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
| ChimerDB4 | ERR315486 | PIM3 | chr22 | 50355459 | TRABD | chr22 | 50635670 |
Top |
Kinase Fusion ORF Analysis |
| Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:50355459/:50635670) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| PIM3 | TRABD |
| FUNCTION: Proto-oncogene with serine/threonine kinase activity that can prevent apoptosis, promote cell survival and protein translation. May contribute to tumorigenesis through: the delivery of survival signaling through phosphorylation of BAD which induces release of the anti-apoptotic protein Bcl-X(L), the regulation of cell cycle progression, protein synthesis and by regulation of MYC transcriptional activity. Additionally to this role on tumorigenesis, can also negatively regulate insulin secretion by inhibiting the activation of MAPK1/3 (ERK1/2), through SOCS6. Involved also in the control of energy metabolism and regulation of AMPK activity in modulating MYC and PPARGC1A protein levels and cell growth. {ECO:0000269|PubMed:15540201, ECO:0000269|PubMed:16818649, ECO:0000269|PubMed:17270021, ECO:0000269|PubMed:17876606, ECO:0000269|PubMed:18593906}. | FUNCTION: Metalloprotease that acts as a negative regulator of the Wnt signaling pathway by mediating the cleavage of the 8 N-terminal residues of a subset of Wnt proteins. Following cleavage, Wnt proteins become oxidized and form large disulfide-bond oligomers, leading to their inactivation. Able to cleave WNT3A, WNT5, but not WNT11. Required for head formation. {ECO:0000269|PubMed:22726442}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of PIM3_TRABD |
| Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
| Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
| PIM3 | Q86V86 | human | LDHA | P00338 | S161 | PkNrVIGsGCNLDsA | |
| PIM3 | Q86V86 | human | STAT5B | P51692 | S731 | TyMDQAPsPAVCPQA | |
| PIM3 | Q86V86 | human | MYC | P01106 | S308 | GHskPPHsPLVLkrC | Myc_N |
| PIM3 | Q86V86 | human | LDHA | P00338 | S319 | EEARLkksADtLWGI | Ldh_1_C |
| PIM3 | Q86V86 | human | BAD | Q92934 | S75 | EIRsRHssyPAGtED | Bcl-2_BAD |
| PIM3 | Q86V86 | human | IRS1 | P35568 | S1101 | GCRRRHssEtFsStP | |
| PIM3 | Q86V86 | human | PSMD2 | Q13200 | S361 | ENNrFGGsGsQVDsA |
| Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
| Enriched GO biological processes of the phosphorylation target genes of the kinase |
| Kinase | GOID | GO term | P.adjust |
| PIM3 | ID | Description | 0.00e+00 |
| PIM3 | GO:0045579 | positive regulation of B cell differentiation | 5.06e-03 |
| PIM3 | GO:0045577 | regulation of B cell differentiation | 1.11e-02 |
| PIM3 | GO:1902105 | regulation of leukocyte differentiation | 1.57e-02 |
| PIM3 | GO:2001244 | positive regulation of intrinsic apoptotic signaling pathway | 1.70e-02 |
| PIM3 | GO:0051347 | positive regulation of transferase activity | 1.70e-02 |
| PIM3 | GO:1903706 | regulation of hemopoiesis | 1.70e-02 |
| PIM3 | GO:0050871 | positive regulation of B cell activation | 1.95e-02 |
| PIM3 | GO:1903131 | mononuclear cell differentiation | 1.95e-02 |
| PIM3 | GO:0045638 | negative regulation of myeloid cell differentiation | 2.07e-02 |
| PIM3 | GO:0010906 | regulation of glucose metabolic process | 2.19e-02 |
| PIM3 | GO:0043280 | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 2.21e-02 |
| PIM3 | GO:0045582 | positive regulation of T cell differentiation | 2.21e-02 |
| PIM3 | GO:2001056 | positive regulation of cysteine-type endopeptidase activity | 2.21e-02 |
| PIM3 | GO:0045621 | positive regulation of lymphocyte differentiation | 2.21e-02 |
| PIM3 | GO:0050864 | regulation of B cell activation | 2.21e-02 |
| PIM3 | GO:2001235 | positive regulation of apoptotic signaling pathway | 2.21e-02 |
| PIM3 | GO:0071456 | cellular response to hypoxia | 2.21e-02 |
| PIM3 | GO:0030183 | B cell differentiation | 2.21e-02 |
| PIM3 | GO:0010950 | positive regulation of endopeptidase activity | 2.21e-02 |
| PIM3 | GO:0036294 | cellular response to decreased oxygen levels | 2.21e-02 |
| PIM3 | GO:0016052 | carbohydrate catabolic process | 2.21e-02 |
| PIM3 | GO:0043281 | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 2.21e-02 |
| PIM3 | GO:0050796 | regulation of insulin secretion | 2.21e-02 |
| PIM3 | GO:0010952 | positive regulation of peptidase activity | 2.21e-02 |
| PIM3 | GO:0030856 | regulation of epithelial cell differentiation | 2.21e-02 |
| PIM3 | GO:0071453 | cellular response to oxygen levels | 2.21e-02 |
| PIM3 | GO:0045580 | regulation of T cell differentiation | 2.21e-02 |
| PIM3 | GO:1902107 | positive regulation of leukocyte differentiation | 2.21e-02 |
| PIM3 | GO:1903708 | positive regulation of hemopoiesis | 2.21e-02 |
| PIM3 | GO:0006109 | regulation of carbohydrate metabolic process | 2.21e-02 |
| PIM3 | GO:2001242 | regulation of intrinsic apoptotic signaling pathway | 2.21e-02 |
| PIM3 | GO:0006006 | glucose metabolic process | 2.21e-02 |
| PIM3 | GO:0090276 | regulation of peptide hormone secretion | 2.21e-02 |
| PIM3 | GO:2000116 | regulation of cysteine-type endopeptidase activity | 2.21e-02 |
| PIM3 | GO:0002791 | regulation of peptide secretion | 2.21e-02 |
| PIM3 | GO:0030073 | insulin secretion | 2.21e-02 |
| PIM3 | GO:0090087 | regulation of peptide transport | 2.21e-02 |
| PIM3 | GO:0045619 | regulation of lymphocyte differentiation | 2.37e-02 |
| PIM3 | GO:0045637 | regulation of myeloid cell differentiation | 2.37e-02 |
| PIM3 | GO:0050679 | positive regulation of epithelial cell proliferation | 2.42e-02 |
| PIM3 | GO:0042180 | cellular ketone metabolic process | 2.54e-02 |
| PIM3 | GO:0019318 | hexose metabolic process | 2.54e-02 |
| PIM3 | GO:0030072 | peptide hormone secretion | 2.54e-02 |
| PIM3 | GO:0002790 | peptide secretion | 2.54e-02 |
| PIM3 | GO:0042593 | glucose homeostasis | 2.54e-02 |
| PIM3 | GO:0046883 | regulation of hormone secretion | 2.54e-02 |
| PIM3 | GO:0050870 | positive regulation of T cell activation | 2.54e-02 |
| PIM3 | GO:0033500 | carbohydrate homeostasis | 2.54e-02 |
| PIM3 | GO:0005996 | monosaccharide metabolic process | 2.54e-02 |
Top |
Related Drugs to PIM3_TRABD |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
| Distribution of the number of studies mentioning PIM3-TRABD and kinase inhibitors the PubMed Abstract (04-01-2024) |
| Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to PIM3_TRABD |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
| MeSH ID | MeSH term |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
| Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
| Clinical Trials from clinicaltrials.gov (06-17-2024) |
| Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |
Copyright 2024-Present -The University of Texas Health Science Center at Houston
Web File Viewing | Emergency Information |Campus Carry|Site Policies |